Sartorius Stedim Biotech (0RG8) Gets a Buy from RBC Capital
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Charles Weston has maintained a Buy rating on Sartorius Stedim Biotech, setting a price target of €210.00. The analyst consensus for the company is a Strong Buy, with a higher price target consensus of €233.00. Weston focuses on the Healthcare sector and has an average return of -7.2% with a 33.07% success rate on his stock recommendations.
RBC Capital analyst Charles Weston maintained a Buy rating on Sartorius Stedim Biotech today and set a price target of €210.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Weston covers the Healthcare sector, focusing on stocks such as Oxford BioMedica, Siegfried Holding AG, and Oxford Nanopore Technologies PLC. According to TipRanks, Weston has an average return of -7.2% and a 33.07% success rate on recommended stocks.
Sartorius Stedim Biotech has an analyst consensus of Strong Buy, with a price target consensus of €233.00.